Comparative Pharmacology
Head-to-head clinical analysis: ACTISITE versus DOXYCYCLINE HYCLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTISITE versus DOXYCYCLINE HYCLATE.
ACTISITE vs DOXYCYCLINE HYCLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
Doxycycline hyclate is a bacteriostatic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex. It also exhibits anti-inflammatory and anti-angiogenic properties.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg daily. For severe infections or certain indications, 100 mg every 12 hours.
None Documented
None Documented
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
18-24 hours in patients with normal renal function; may increase to 24-48 hours in renal impairment; clinical context: allows once- or twice-daily dosing.
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-30% eliminated in feces via biliary secretion and nonbiliary routes; the remainder is metabolized. Enterohepatic circulation contributes to prolonged half-life.
Category C
Category D/X
Tetracycline Antibiotic
Tetracycline Antibiotic